mouse anti hla dr dp dq  (Absolute Biotech Inc)

Journal: Biomarker Research

Article Title: Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer

doi: 10.1186/s40364-025-00797-9

Figure Lengend Snippet: KAT2B Regulates tsMHC-II Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels of HLA-DR, DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC

Article Snippet: All the antibodies used in this study were as follows: tsMHC-II: Monoclonal Mouse Anti-Human HLA-DR/DP/DQ/DX Antibody (Clone.CR3/43, 1:1000, sc-53302, Santa-Cruz); PanCK: Monoclonal Mouse Anti-Human Cytokeratin Antibody (Clone.AE1/AE3, GA053, 1:100, Dako); tsMHC-I: Monoclonal Mouse Anti-HLA Class 1 ABC Antibody (Clone.EMR8-5, ab70328, 1:200, Abcam); CD4: Monoclonal Mouse Anti-Human CD4 Antibody (Clone.4B12, IR649, 1:100, Dako); CD8: Monoclonal Mouse Anti-Human CD8 Antibody (Clone.C8/144B, IR623, 1:150, Dako).

Techniques: Biomarker Discovery, Flow Cytometry, Expressing, Drug discovery, ChIP-sequencing

Journal: Biomarker Research

Article Title: Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer

doi: 10.1186/s40364-025-00797-9

Figure Lengend Snippet: KAT2B Acetylation of CIITA Promoter Upregulates Tumor-Specific MHC-II Expression Enhancing NAC-IT Efficacy. A Relative RNA expression of KAT2B and CIITA in MDA-MB-231 cells with KAT2B knockdown versus control group (Left); Relative RNA expression of KAT2B and CIITA in BT-549 and MDA-MD-157 cells with KAT2B overexpression versus control group (Right). B Flow cytometry analysis showing proportion of tsMHC-II positive tumor cells in MDA-MB-231 with KAT2B knockdown versus control group (Left); Proportion of tsMHC-II positive tumor cells in BT-549 and MDA-MD-157 with KAT2B overexpression versus control group (Right). C. Radar plots of flow cytometry data for MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. D. Western Blot analysis of KAT2B, CIITA, HLA-DR, and Beta-Actin protein expression in MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. E. Schematic diagram of ChIP-qPCR primer design for the 1000 bp CIITA promoter fragments. F. ChIP-qPCR bar graph showing KAT2B binding enrichment at CIITA promoter fragments P1, P2, P3, and P4. G-H. ChIP-qPCR bar graphs showing enrichment of KAT2B, H3K14ac, and H4K8ac at the CIITA promoter P1 segment in MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. I. Fluorescence imaging results of co-culture between tsMHC-II high-expression TNBC PDOs and paired CD44 + CD4 + effector T cells. Red indicates CD44 + CD4 + effector T cells, and green represents tsMHC-II high-expression TNBC PDOs. Scale bar: 50 μm. J-K. Tumor viability ( J ) and IFN-γ + CD4 + T-cell proportion ( K ) in PDO immune co-culture groups treated with paclitaxel, doxorubicin, or aPD1, respectively. *means p < 0.05; **means p < 0.01; ***means p < 0.001

Article Snippet: All the antibodies used in this study were as follows: tsMHC-II: Monoclonal Mouse Anti-Human HLA-DR/DP/DQ/DX Antibody (Clone.CR3/43, 1:1000, sc-53302, Santa-Cruz); PanCK: Monoclonal Mouse Anti-Human Cytokeratin Antibody (Clone.AE1/AE3, GA053, 1:100, Dako); tsMHC-I: Monoclonal Mouse Anti-HLA Class 1 ABC Antibody (Clone.EMR8-5, ab70328, 1:200, Abcam); CD4: Monoclonal Mouse Anti-Human CD4 Antibody (Clone.4B12, IR649, 1:100, Dako); CD8: Monoclonal Mouse Anti-Human CD8 Antibody (Clone.C8/144B, IR623, 1:150, Dako).

Techniques: Expressing, RNA Expression, Knockdown, Control, Over Expression, Flow Cytometry, Western Blot, ChIP-qPCR, Binding Assay, Fluorescence, Imaging, Co-Culture Assay